cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
20 own
21 watching
Current Price
$55.95
$-0.08
(-0.14%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
10,508.09M
52-Week High
52-Week High
60.20000
52-Week Low
52-Week Low
31.45000
Average Volume
Average Volume
1.92M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
38.4575
iconMarket Capitalization10,508.09M
icon52-Week High60.20000
icon52-Week Low31.45000
iconAverage Volume1.92M
iconDividend Yield--
iconP/E Ratio38.4575
What does the Stockal+Disclaimer.pdf do?
Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment provides formulation, development, and manufacturing services for softgels, which are used in a range of customer products, including prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics. Its principal softgel technologies include traditional softgel capsules, and Vegicaps and OptiShell capsules. The Drug Delivery Solutions segment formulates, develops, and manufactures prescription, and consumer and animal health products using proprietary technologies, including OptiMelt, OptiPact, OptiForm, and Zydis, as well as other proprietary and conventional drug delivery technologies, such as prefilled syringes; manufactures blow-fill seal unit dose, including ADVASEPT technology; develops biologic cell line, including GPEx and SMARTag technologies; and provides analytical and bioanalytical development, and testing services, as well as offers respiratory products formulation and manufacturing, micronization and particle engineering, and regulatory consulting services. The Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials for customer required patient kits. This segment also offers FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical and biotechnology companies; and consumer health companies, as well as companies in other healthcare market segments, such as animal health and medical devices, and companies in industries, including cosmetics. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Business Wire
10 months ago
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Catalent, Inc. (NYSE: CTLT) on behalf of long-term stockholders following a class action complaint that was filed against Catalent on February 28, 2023 with a Class...
PR Newswire
10 months ago
Thinking about buying stock in T Rowe Price, Ross Stores, Davita, Catalent, or Finch Therapeutics? Thinking about buying stock in T Rowe Price, Ross Stores, Davita, Catalent, or Finch Therapeutics? PR Newswire NEW YORK, June 13, 2023 NEW YORK, June 13, 2023 /PRNewswire/ -- InvestorsObserver issues...
Globe Newswire
11 months ago
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Alico, Inc. (NASDAQ: ALCO) Johnson Fistel, LLP is investigating potential claims on behalf of Alico, Inc. ("Alico" or the "Company") (NASDAQ: ALCO) against certain of its officers and directors. If you are a current, long-term shareholder of Alico holding ...
Globe Newswire
1 year ago
SAN FRANCISCO, April 25, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Catalent, Inc. (NYSE: CTLT) investors who suffered substantial losses submit your losses now. Class Period: Aug. 30, 2021 Oct. 31, 2022Lead Plaintiff Deadline: Apr. 25, 2023Visit: https://www.hbsslaw.com/investor-fraud/CTLT ...
Business Wire
1 year ago
The Law Offices of Frank R. Cruz reminds investors of the upcoming April 25, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Catalent, Inc. (Catalent or the Company) (NYSE: CTLT) securities between August 30, 2021 and October 31, 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$55.95
$-0.08
(-0.14%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$42.45
$0.61 (1.46 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$12.56
$-1.05 (-7.71 %)
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc.
$4.56
$-0.07 (-1.51 %)
United Therapeutics Corporation
United Therapeutics Corporation
$237.00
$2.53 (1.08 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$42.45
$0.61 (1.46 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$12.56
$-1.05 (-7.71 %)
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc.
$4.56
$-0.07 (-1.51 %)
United Therapeutics Corporation
United Therapeutics Corporation
$237.00
$2.53 (1.08 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00